107 related articles for article (PubMed ID: 11888917)
1. Effects of SP500263, a novel, potent antiestrogen, on breast cancer cells and in xenograft models.
Brady H; Desai S; Gayo-Fung LM; Khammungkhune S; McKie JA; O'Leary E; Pascasio L; Sutherland MK; Anderson DW; Bhagwat SS; Stein B
Cancer Res; 2002 Mar; 62(5):1439-42. PubMed ID: 11888917
[TBL] [Abstract][Full Text] [Related]
2. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
3. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.
Osborne CK; Hobbs K; Clark GM
Cancer Res; 1985 Feb; 45(2):584-90. PubMed ID: 3967234
[TBL] [Abstract][Full Text] [Related]
4. Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice.
Schafer JM; Lee ES; O'Regan RM; Yao K; Jordan VC
Clin Cancer Res; 2000 Nov; 6(11):4373-80. PubMed ID: 11106256
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma.
Sonpavde G; Okuno N; Weiss H; Yu J; Shen SS; Younes M; Jian W; Lerner SP; Smith CL
Urology; 2007 Jun; 69(6):1221-6. PubMed ID: 17572228
[TBL] [Abstract][Full Text] [Related]
6. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
7. Lead identification of a potent benzopyranone selective estrogen receptor modulator.
McKie JA; Bhagwat SS; Brady H; Doubleday M; Gayo L; Hickman M; Jalluri RK; Khammungkhune S; Kois A; Mortensen D; Richard N; Sapienza J; Shevlin G; Stein B; Sutherland M
Bioorg Med Chem Lett; 2004 Jul; 14(13):3407-10. PubMed ID: 15177442
[TBL] [Abstract][Full Text] [Related]
8. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
[TBL] [Abstract][Full Text] [Related]
9. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
10. Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice.
Ju YH; Fultz J; Allred KF; Doerge DR; Helferich WG
Carcinogenesis; 2006 Apr; 27(4):856-63. PubMed ID: 16399773
[TBL] [Abstract][Full Text] [Related]
11. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
Johnston SR
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
[TBL] [Abstract][Full Text] [Related]
12. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Maeda T; Ke HZ; Simmons H; Thompson D
Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
[TBL] [Abstract][Full Text] [Related]
13. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
Palkowitz AD; Glasebrook AL; Thrasher KJ; Hauser KL; Short LL; Phillips DL; Muehl BS; Sato M; Shetler PK; Cullinan GJ; Pell TR; Bryant HU
J Med Chem; 1997 May; 40(10):1407-16. PubMed ID: 9154963
[TBL] [Abstract][Full Text] [Related]
14. Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis.
Salvo VA; Boué SM; Fonseca JP; Elliott S; Corbitt C; Collins-Burow BM; Curiel TJ; Srivastav SK; Shih BY; Carter-Wientjes C; Wood CE; Erhardt PW; Beckman BS; McLachlan JA; Cleveland TE; Burow ME
Clin Cancer Res; 2006 Dec; 12(23):7159-64. PubMed ID: 17145841
[TBL] [Abstract][Full Text] [Related]
15. Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat.
Sutherland MK; Brady H; Gayo-Fung LM; Leisten J; Lipps SG; McKie JA; O'Leary E; Patnaik N; Anderson DW; Bhagwat SS; Stein B
Calcif Tissue Int; 2003 Jun; 72(6):710-6. PubMed ID: 14563000
[TBL] [Abstract][Full Text] [Related]
16. Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells.
Hui AM; Zhang W; Chen W; Xi D; Purow B; Friedman GC; Fine HA
Cancer Res; 2004 Dec; 64(24):9115-23. PubMed ID: 15604281
[TBL] [Abstract][Full Text] [Related]
17. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
18. Differential response of estrogen receptors alpha and beta to SP500263, a novel potent selective estrogen receptor modulator.
Brady H; Doubleday M; Gayo-Fung LM; Hickman M; Khammungkhune S; Kois A; Lipps S; Pierce S; Richard N; Shevlin G; Sutherland MK; Anderson DW; Bhagwat SS; Stein B
Mol Pharmacol; 2002 Mar; 61(3):562-8. PubMed ID: 11854436
[TBL] [Abstract][Full Text] [Related]
19. A dietary supplement for female sexual dysfunction, Avlimil, stimulates the growth of estrogen-dependent breast tumors (MCF-7) implanted in ovariectomized athymic nude mice.
Ju YH; Doerge DR; Helferich WG
Food Chem Toxicol; 2008 Jan; 46(1):310-20. PubMed ID: 17919800
[TBL] [Abstract][Full Text] [Related]
20. Estrogenic and antiestrogenic effects of raloxifene on collagen metabolism in breast cancer MCF-7 cells.
Wołczynski S; Surazyński A; Swiatecka J; Pałka J
Gynecol Endocrinol; 2001 Jun; 15(3):225-33. PubMed ID: 11447735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
